RAPT Therapeutics, Inc. 8-K

What Happened

• RAPT Therapeutics, Inc. filed a Form 8-K on January 14, 2026, reporting it will participate in the 44th Annual J.P. Morgan Healthcare Conference (JPM Conference). The company attached its corporate presentation as Exhibit 99.1 to the filing. The 8-K notes the presentation materials are provided under Regulation FD and are incorporated by reference into the report.

Key Details

• Filing date: January 14, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Event: 44th Annual J.P. Morgan Healthcare Conference (JPM Conference).
• Exhibit: Corporate presentation included as Exhibit 99.1.
• Legal note: The materials are not deemed “filed” for purposes of Section 18 of the Exchange Act or certain liabilities under the Securities Act, and are not to be incorporated by reference into other filings unless expressly stated.
• Report signed by Rodney Young, Chief Financial Officer.

Why It Matters

• Participation and the posted presentation give investors direct access to RAPT’s current corporate updates (strategy, pipeline, or financial commentary as disclosed in the slides).
• This is a routine, Regulation FD-compliant investor communication — useful for shareholders seeking the company’s latest public messaging ahead of or during the JPM Conference.
• Investors should review Exhibit 99.1 in the 8-K for specifics; the filing itself clarifies the legal status of the presentation materials for other SEC filings.